This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bremnes, Y. Articles by Gram, I. T. Search for Related Content PubMed PubMed Citation Articles by Bremnes, Y. Articles by Gram, I. T.

Insulin-like Growth Factor and Mammographic Density in Postmenopausal Norwegian Women

¹ Institute of Community Medicine, University of Tromsø; ² Department of Radiology, Center for Breast Imaging, University Hospital of North Norway, Tromsø, Norway; ³ Department of Preventive Medicine/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California; ⁴ Department of Nutrition, University of Oslo, Oslo, Norway; ⁵ IARC-WHO, Lyon, France; and ⁶ Deutsches Krebsforschungszentrum, Heidelberg, Germany

Requests for reprints: Yngve Bremnes, Institute of Community Medicine, University of Tromsø, N-9037 Tromsø, Norway. Phone: 47-77-64-63-05; Fax: 47-77-64-48-31. E-mail: yngve.bremnes{at}ism.uit.no

Insulin-like growth factor-I (IGF-I) is associated with breast cancer risk among premenopausal women but rarely among postmenopausal women. Recent data from two European studies suggested an increased risk of breast cancer with increasing levels of IGF-I among women >50 years old or among postmenopausal hormone therapy users 55 years old. Mammographic density is one of the strongest risk factors, and possibly an intermediate marker, for breast cancer. We examined the relationship between IGF and mammographic density among postmenopausal women overall and according to hormone therapy use. Altogether, 977 postmenopausal participants in the Norwegian governmental mammographic screening program had IGF concentrations measured by ELISA. Mammograms were classified according to percent and absolute mammographic densities using a previously validated computer-assisted method. After adjustment for age, number of children, age at menopause, body mass index, and hormone therapy use, both plasma IGF-I concentration (P_trend = 0.02) and IGF-I/IGF binding protein 3 ratio (P_trend = 0.02) were positively associated with percent mammographic density. The magnitudes of differences in percent mammographic density between women in the lowest and highest quartiles of IGF-I concentrations were 1.5% absolute difference and 21% relative difference. These associations were similar with absolute mammographic density as the outcome variable. When the analyses were stratified according to hormone therapy use, the associations between IGF-I and mammographic density were significant among noncurrent users (P_trend = 0.03). In conclusion, we found a positive but weak association between plasma IGF-I concentrations and both percent and absolute mammographic densities among postmenopausal women. These associations were found among noncurrent hormone therapy users but not among current users. (Cancer Epidemiol Biomarkers Prev 2007;16(1):57–62)